| 摘要 |
PROBLEM TO BE SOLVED: To provide controlled release oral dosage formulations containing tasocitinib, which is an immunosuppressive agent.SOLUTION: An oral dosage formulation comprises 1-60 wt. % of tasocitinib, and 5-80 wt.% of a non-erodible material selected from ethylcellulose, celluloseester, copolymers of methacryl acid or methacrylic acid esters, polyvinyl acetate and polyvinyl acetate copolymers. The oral dosage formulation exhibits drug release of less than 10% within 2 hours, and drug release of more than 80% within 4-8 hours.SELECTED DRAWING: None |
